Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07126119) titled 'Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC' on Aug. 9.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Tianjin Medical University Second Hospital
Condition:
Upper Tract Urothelial Carcinoma
Neoadjuvant Therapy
PD-1 Inhibitor
Nab-paclitaxel
Intervention:
Drug: Nab-Paclitaxel
Drug: Tislelizumab
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: July 5, 2025
Target Sample Size: 35
Countries of Recruitment:
China
To know more, visit ...